# Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

> **NCT06305832** · PHASE2 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 102 (estimated)

## Conditions studied

- Prostate Cancer
- Biochemical Recurrence

## Interventions

- **DRUG:** Rezvilutamide
- **DRUG:** Androgen deprivation therapy (ADT)
- **RADIATION:** SRT

## Key facts

- **NCT ID:** NCT06305832
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-07
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305832, "Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06305832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*